SequelSEC

SPRUCE BIOSCIENCES, INC. SPRB

Pharmaceutical Preparations · CIK 0001683553 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$36.51M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

SPRUCE BIOSCIENCES, INC. (SPRB) reported revenue of $0 and net income of -$38.97M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from SPRUCE BIOSCIENCES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

SPRUCE BIOSCIENCES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Revenue$0$4.91M$10.09M$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$36.51M-$56.15M-$51.99M-$47.28M
Net income-$38.97M-$53.04M-$47.92M-$46.18M
Research & development$19.52M$46.42M$49.43M$35.20M
Weighted-average diluted sharesUnavailableUnavailableshares 38.51Mshares 23.53M
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0
Diluted EPS$-50.83$-96.40$-1.24$-1.96
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$16.99M$14.64M$12.65M$12.08M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

SPRUCE BIOSCIENCES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$48.91M$38.75M$96.34M$24.49M
Total assets$53.02M$45.21M$103.95M$85.65M
Current assets$52.11M$44.21M$102.18M$83.61M
Total liabilities$10.50M$16.39M$27.44M$17.16M
Current liabilities$10.09M$15.25M$24.46M$12.45M
Total equity incl. NCI$42.52M$28.82M$76.51M$68.49M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable$0
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debt$0$124.00K$1.72M$3.29M
Accounts payable$943.00K$1.30M$3.33M$1.43M

Cash flow

SPRUCE BIOSCIENCES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$33.33M-$55.96M-$33.28M-$41.68M
Capital expendituresUnavailable$0$7.00K$8.00K
Investing cash flowUnavailable$0$55.78M$23.69M
Financing cash flow$43.48M-$1.62M$49.14M-$241.00K
Net change in cashUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$2.57M$5.35M$4.62M$3.63M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$21.00K$46.00K$70.00K$74.00K

Derived

SPRUCE BIOSCIENCES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailable-$33.28M-$41.69M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-1143.4%-515.3%Unavailable
FCF marginUnavailableUnavailable-329.9%Unavailable
SBC / revenueUnavailable108.9%45.8%Unavailable
Current ratio5.17x2.90x4.18x6.72x
Revenue YoY growth-100.0%-51.3%UnavailableUnavailable
Net marginUnavailable-1079.9%-475.0%Unavailable
R&D / revenueUnavailable945.2%490.0%Unavailable
CapEx / revenueUnavailableUnavailable0.1%Unavailable
Long-term debt / equity0.00xUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SPRB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.